DDInter1087 DDInter122
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Lonafarnib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Lonafarnib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Lonafarnib {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Lonafarnib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Lonafarnib may lead to a major life threatening interaction when taken with Enzalutamide
Lonafarnib may lead to a major life threatening interaction when taken with Halofantrine